Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is expected to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of ($1.01) per share and revenue of $0.35 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Revolution Medicines Stock Down 2.2 %

Shares of RVMD stock opened at $41.34 on Monday. The firm has a market cap of $6.95 billion, a P/E ratio of -11.52 and a beta of 1.45. The business has a 50-day moving average price of $42.49 and a two-hundred day moving average price of $46.29. Revolution Medicines has a 12-month low of $28.65 and a 12-month high of $62.40.

Insider Activity at Revolution Medicines

In other news, Director Thilo Schroeder acquired 1,304,347 shares of the stock in a transaction on Thursday, December 5th. The stock was acquired at an average price of $46.00 per share, with a total value of $59,999,962.00. Following the completion of the transaction, the director now owns 2,096,612 shares of the company’s stock, valued at $96,444,152. This represents a 164.64 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Jack Anders sold 2,635 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $119,629.00. Following the completion of the sale, the chief financial officer now directly owns 96,470 shares in the company, valued at $4,379,738. This represents a 2.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,678 shares of company stock worth $847,981 over the last ninety days. 8.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on RVMD. UBS Group lifted their target price on shares of Revolution Medicines from $65.00 to $71.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $68.00 price objective on shares of Revolution Medicines in a report on Tuesday, December 3rd. Guggenheim boosted their target price on Revolution Medicines from $82.00 to $87.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Wedbush restated an “outperform” rating and set a $70.00 price target on shares of Revolution Medicines in a research report on Monday, December 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on Revolution Medicines from $63.00 to $71.00 and gave the company an “overweight” rating in a research report on Tuesday, December 3rd. Eleven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $66.25.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.